Stocks · News reference
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $230
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Maintains Outperform Rating on Belite Bio
Leerink Partners has reaffirmed its 'Outperform' rating for Belite Bio.
Leerink Partners Maintains Outperform on Belite Bio, Raises Price Target to $215
Mizuho Adjusts Price Target on Belite Bio to $230 From $221, Maintains Outperform Rating
Mizuho Securities has updated its price target for Belite Bio, increasing it to $230 from the previous $221 while maintaining an Outperform rating.
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results
Belite Bio, Inc. announced its unaudited financial results for the third quarter ended September 30, 2026, and provided a corporate update regarding its lead product candidate, tinlarebant.
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
Belite Bio, Inc. has scheduled a conference call and webcast for November 12, 2026, to review its financial results for the third quarter of 2026.